News

Ono and Kyowa Hakko Kirin will be responsible for conducting the trial in Japan, which will focus on evaluating the safety, tolerability and anti-tumor activity of the combination

Celebrex is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis as well as for the management of acute pain in

Earlier this month, Vimizim was also approved in Australia for the treatment of this rare, severely debilitating and progressive disease that previously had no approved, standard-of-care treatment other

Cancer therapy often results in the patient becoming very sick due to toxicity and off-target effects of certain drugs used to treat patients. ADCs take advantage of the

Consistent with prior guidance, earlier this year, Mast Therapeutics submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA), together with the protocol

INNs facilitate the identification of active pharmaceutical ingredients, and each INN is a globally recognized unique name. As a novel, orally available, selective tyrosine kinase inhibitor of the

HealthPatch MD can be used with Medidata’s industry-leading technology platform (Medidata Clinical Cloud) and its mobile app for patient-reported outcomes (Medidata Patient Cloud) to further remote patient monitoring,

ZipDose products allow people to take their medications with greater ease, potentially increasing adherence and improving symptom management. According to the company, these products achieve dosage strengths that

Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies. Can-Fite reports today that it received positive pre-clinical data